Background. Neuropsychiatric symptoms (NPS) are a common and potentially serious manifestation of Parkinsons disease (PD) but are frequently overlooked in favor of a focus on motor symptomatology. Here, we conducted a literature review of the prevalence and type of NPS experienced by PD patients with a clinically defined course of their illness. Methods. We identified reports of NPS in patients with PD and mean disease duration over 3 years. Three databasesPubMed, Scopus, and Dialnetwere searched for relevant literature published between 2010 and 2020. Predefined exclusion criteria were applied prior to a descriptive analysis of the literature base. Results. In all, 87 unique reports were identified and 30 met inclusion and exclusion criteria. These included 7142 patients with PD (male: 67.3; mean age: 66.2 years; mean disease duration: 6.7 years). The most frequent NPS were mood disorders (apathy, depression, and anxiety), psychosis, and impulse control disorders (ICD). Treatment with dopamine agonists was identified as an important risk factor for ICD. Co-occurrence of NPS and cognitive dysfunction was also evidenced in a number of studies. Patients with more significant cognitive deficits and higher levels of NPS appeared to be of older age with a longer disease duration and to have more severe motor symptoms. Conclusions. NPS, most commonly mood disorders (apathy, depression, and anxiety), psychosis, and ICDs are frequent manifestations of PD. The results of this review reflect the need to develop unified validated assessment protocols for NPS in PD, as well as to improve their management in clinical practice.
5 May 2026 in International Journal of Neural Systems
Introduction Cortico-subcortical dysfunction from dopaminergic depletion is a hallmark of Parkinson’s disease (PD). Modulating primary motor cortex (M1) excitability with intermittent theta burst stimulation (iTBS) may restore network integrity in PD by targeting neurobiological changes at excitatory, structural, and serological levels. This study aimed to demonstrate the clinical and neurobiological effects of bilateral M1 iTBS in patients with PD. Methods Seventeen patients with Hoehn-Yahr stage II–III PD in the on-medication state underwent daily bilateral M1 iTBS sessions for 5 consecutive days in a randomized, double-blind, placebo-controlled, crossover design. The primary clinical outcomes were the relative change from baseline at four follow-up points after the final iTBS session, measured by the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Parts II, III, and IV. Changes in corticospinal excitability, structural brain imaging, and serum biomarkers of neurodegeneration, astrocytic activation, and neuroplasticity were also assessed. Results Real iTBS induced a significant improvement in MDS-UPDRS Part III scores, yielding more than twice the therapeutic benefit observed with sham stimulation. Responders (> 20% improvement) showed a mean 9-point improvement. Similarly, real iTBS stimulation resulted in an increase in corticospinal excitability of the clinically most affected hemisphere. In responders, serum brain-derived neurotrophic factor levels increased along with an increase in left ventral diencephalon volume, which was the strongest predictor of clinical response. Conclusion Bilateral M1 iTBS may represent a valuable adjunctive therapeutic option for pharmacological treatment of motor symptoms in patients with PD by promoting structural brain changes and enhancing synaptic plasticity in intermediate disease stages. Clinical Trial Registration https://clinicaltrials.gov/: NCT06840145, retrospectively registered on September 9, 2023.
Background: Slowed information processing speed (IPS) is an early and prevalent cognitive feature of relapsing–remitting multiple sclerosis (RRMS), although its neurobiological mechanisms remain poorly understood. This study investigated the multimodal basis of IPS impairment in mildly disabled RRMS patients by integrating structural MRI, resting-state functional connectivity (FC), and serum biomarkers of neuroaxonal (sNfL) and astrocytic (sGFAP) injury.Methods: Forty-three individuals with RRMS and 29 healthy controls (HCs) underwent neuropsychological assessment, blood sampling, and MRI scanning. Gray matter (GM) voxel-based morphometry and resting-state independent component analysis (ICA) were performed. RRMS patients were stratified into high-IPS and low-IPS subgroups based on their performance in neuropsychological tests.Results: Compared with HCs, RRMS patients exhibited significant IPS impairment, bilateral thalamic GM atrophy, and elevated sNfL levels. Subgroup stratification revealed a clear dissociation: low-IPS patients showed pronounced bilateral thalamic atrophy, higher white matter lesion volume, and elevated sNfL and sGFAP levels relative to high-IPS patients. In contrast, high-IPS patients showed no evidence of GM atrophy or abnormal sNfL levels compared with HCs, but exhibited significantly increased FC within sensorimotor cortical regions. Stepwise multiple regression identified thalamic GM volume as the strongest independent predictor of IPS, with sGFAP levels and sensorimotor network FC providing significant incremental explanatory value.Conclusions: These findings reveal a clinico-biological dissociation in RRMS. While IPS impairment is driven by neuroaxonal injury and structural collapse, cognitive preservation is maintained through adaptive sensorimotor network reorganization. This functional compensation appears to mitigate cognitive decline until a critical structural damage threshold is reached.